Agenus (AGEN) Stock Overview
A clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
AGEN Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Agenus Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.32 |
| 52 Week High | US$8.85 |
| 52 Week Low | US$2.71 |
| Beta | 1.4 |
| 1 Month Change | 46.11% |
| 3 Month Change | 136.89% |
| 1 Year Change | 61.59% |
| 3 Year Change | -74.23% |
| 5 Year Change | -94.09% |
| Change since IPO | -99.90% |
Recent News & Updates
Narrative Update • Aug 15
AGEN: Refocused Colorectal Cancer Pipeline And Funding Will Support Future Upside
Agenus sees its analyst fair value estimate move from $30.00 to $19.50 as analysts recalibrate long term assumptions on revenue growth, profitability and future P/E, following recent price target changes related to financing plans and the refocused pipeline. Analyst Commentary Recent Street research on Agenus highlights a mix of optimism about the refocused pipeline and caution around financing and execution.
Narrative Update • Jul 31
AGEN: Refocused Colon Cancer Program And New Funding Will Drive Upside
Agenus is in focus after analysts lifted their price target to $14 from $8, citing a revised view on fair value, updated growth and margin assumptions, and a higher future P/E multiple following recent research that highlights the company’s refocused oncology pipeline and $340M private placement. Analyst Commentary on Agenus Recent research on Agenus highlights a mix of optimism around the oncology pipeline and the US$340M private placement, alongside some clear areas where analysts see meaningful execution and valuation risks.Recent updates
Narrative Update • Aug 15
AGEN: Refocused Colorectal Cancer Pipeline And Funding Will Support Future Upside
Agenus sees its analyst fair value estimate move from $30.00 to $19.50 as analysts recalibrate long term assumptions on revenue growth, profitability and future P/E, following recent price target changes related to financing plans and the refocused pipeline. Analyst Commentary Recent Street research on Agenus highlights a mix of optimism about the refocused pipeline and caution around financing and execution.Narrative Update • Jul 31
AGEN: Refocused Colon Cancer Program And New Funding Will Drive Upside
Agenus is in focus after analysts lifted their price target to $14 from $8, citing a revised view on fair value, updated growth and margin assumptions, and a higher future P/E multiple following recent research that highlights the company’s refocused oncology pipeline and $340M private placement. Analyst Commentary on Agenus Recent research on Agenus highlights a mix of optimism around the oncology pipeline and the US$340M private placement, alongside some clear areas where analysts see meaningful execution and valuation risks.Narrative Update • Jul 13
AGEN: Neoadjuvant Colorectal Cancer Focus And Funding Will Drive Bullish Reassessment
Agenus' analyst price target has been reset from $15.50 to $30.00. Analysts point to the company's refocus on botensilimab and balstilimab in neoadjuvant microsatellite stable colorectal cancer, as well as the recently announced $340.0m private placement, as key drivers of their updated view.Narrative Update • Jun 23
AGEN: Late-Stage Cancer Pipeline And Access Programs Will Drive Future Upside
Analysts have revised their price target on Agenus to reflect a lower assumed future P/E of 24.80x, down from 34.01x, alongside updated views on revenue growth and profit margins that together temper growth expectations while assuming a stronger profitability profile. What’s in the News for Agenus Agenus is advancing its botensilimab plus balstilimab program with new retrospective data using Noetik’s AI based TARIO-2 model to analyze routine H&E tumor images and identify spatial tumor microenvironment patterns linked with clinical outcomes in solid tumors, including microsatellite stable metastatic colorectal cancer, ovarian cancer, and sarcomas, with results to be presented at the 2026 ASCO Annual Meeting.Narrative Update • Jun 08
AGEN: Phase 3 Colorectal Cancer Trial Will Support Bullish Reassessment
Analyst price targets for Agenus have been reaffirmed at $15.50, with modest adjustments to the discount rate, revenue growth assumptions, profit margin and forward P/E reflecting analysts' updated view of the stock's risk profile and earnings potential. What's in the News Agenus is advancing its botensilimab plus balstilimab (BOT+BAL) program with multiple data disclosures, including new Phase 2 results in advanced cutaneous melanoma and published Phase 1b data in treatment refractory hepatocellular carcinoma.Narrative Update • May 24
AGEN: Phase 3 Colorectal Cancer Trial Will Drive Bullish Reassessment
Analysts now set a higher price target for Agenus, moving their fair value estimate from $12.33 to $15.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Phase 2 data from the C-800-23 study in advanced cutaneous melanoma showed a 22% confirmed objective response rate for botensilimab plus balstilimab, with median overall survival of 16.6 months and a 42% 2 year overall survival rate in the overall cohort, and no treatment related deaths reported (Key Developments).Narrative Update • May 04
AGEN: Late Stage Cancer Data And Access Programs Will Drive Future Upside
Analysts have reduced their price targets on Agenus by $8.00 after updating their assumptions for revenue growth, profit margins, and future P/E levels to reflect a more conservative view of the stock’s valuation inputs. What's in the News Agenus is presenting four botensilimab and balstilimab abstracts at the 2026 ASCO Annual Meeting, including first Phase 2 data in advanced cutaneous melanoma and a trial-in-progress update on the Phase 3 CO.33/BATTMAN colorectal cancer study (Key Developments).Narrative Update • Apr 20
AGEN: Late Stage Gastrointestinal Cancer Data Will Drive Future Upside
Analysts have nudged their price target on Agenus higher to $8.00, reflecting updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Agenus reported Phase II data from a Memorial Sloan Kettering trial combining botensilimab, balstilimab, agenT-797, ramucirumab, and paclitaxel in advanced PD-1 refractory gastroesophageal adenocarcinoma, with a 77% disease control rate in 17 patients and a subset showing survival beyond 20 months (AACR Annual Meeting 2026).Narrative Update • Apr 04
AGEN: Expanded Late-Stage Trials And Access Programs Will Drive Future Upside
Analysts have raised their price target on Agenus from $6.00 to $8.00. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and a higher future P/E of 28.67x compared with 19.01x previously.Narrative Update • Aug 17
Advanced Immuno-Oncology Therapies Will Reshape Future Cancer Care
The notable upward revision in Agenus’s fair value target is primarily driven by significant improvements in net profit margin and a modest increase in forecasted revenue growth, resulting in a consensus analyst price target increase from $11.00 to $12.33. What's in the News Agenus' botensilimab and balstilimab immunotherapy programs continue to show promising clinical progress, with new survival data and presentations at major oncology congresses, including a 42% two-year survival rate and 21-month median OS in immunotherapy-resistant MSS metastatic colorectal cancer.
New Narrative • Apr 08
BOT/BAL Trials And Cost Reductions Will Shape Future Advances
Strategic cost reduction and asset monetization aim to strengthen financials and fund key projects like BOT/BAL, enhancing potential revenues and earnings.Seeking Alpha • Jul 24
Agenus: Novel Drugs That Just Are Not Novel
Summary Agenus is a small biotech company focused on developing cancer treatments, with a history of poor stock performance and financial struggles. The company's primary assets in its pipeline are Botensilimab and Balstilimab, which have shown limited efficacy in pre-clinical and clinical trials. Recent FDA meeting and phase 2 metastatic colorectal cancer data plummeted AGEN stock 60%, due to discouragement to file for accelerated approval. Further funding is likely to be required soon, considering high cash burn rates and the upcoming phase 3 trial in mCRC. Read the full article on Seeking AlphaAnalysis Article • May 21
There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise
Agenus Inc. ( NASDAQ:AGEN ) shareholders are no doubt pleased to see that the share price has bounced 102% in the last...Analysis Article • May 09
Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results
Shareholders might have noticed that Agenus Inc. ( NASDAQ:AGEN ) filed its quarterly result this time last week. The...Shareholder Returns
| AGEN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.6% | 0.5% | 0.6% |
| 1Y | 61.6% | 35.8% | 20.1% |
Return vs Industry: AGEN exceeded the US Biotechs industry which returned 35.8% over the past year.
Return vs Market: AGEN exceeded the US Market which returned 20.1% over the past year.
Price Volatility
| AGEN volatility | |
|---|---|
| AGEN Average Weekly Movement | 26.7% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AGEN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AGEN's weekly volatility has increased from 17% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 81 | Garo Armen | www.agenusbio.com |
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.
Agenus Inc. Fundamentals Summary
| AGEN fundamental statistics | |
|---|---|
| Market cap | US$329.55m |
| Earnings (TTM) | US$91.80m |
| Revenue (TTM) | US$132.69m |
3.6x
P/E Ratio2.5x
P/S RatioIs AGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGEN income statement (TTM) | |
|---|---|
| Revenue | US$132.69m |
| Cost of Revenue | -US$18.06m |
| Gross Profit | US$150.75m |
| Other Expenses | US$58.96m |
| Earnings | US$91.80m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Sep 10, 2026
| Earnings per share (EPS) | 2.04 |
| Gross Margin | 113.61% |
| Net Profit Margin | 69.18% |
| Debt/Equity Ratio | -14.6% |
How did AGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/17 16:13 |
| End of Day Share Price | 2026/08/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Agenus Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Michael King | Citizens JMP Securities, LLC |
| Emily Bodnar | H.C. Wainwright & Co. |